AN
ANIP.US ANI Pharmaceuticals Inc
- Market cap
- USD 1.62B
- P/E
- 14.2x
- P/B
- 2.53x
- ROE
- 18.7%
- Dividend yield
- 0.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ANIP.US undervalued?
Graham numberANIP.US trades 26.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ANI Pharmaceuticals Inc fundamental analysis
No fundamental analysis for ANI Pharmaceuticals Inc yet.
ANI Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty …
Full company profileANI Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ANI Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 129M | 177M | 202M | 207M | 208M | 216M | 316M | 487M | 614M | 883M | 1.06B |
| Gross Profit | 79.8M | 97.8M | 129M | 143M | 121M | 116M | 178M | 305M | 364M | 451M | 624M |
| Operating Income | 20.1M | 28.3M | 35.4M | 16.4M | -16.0M | -39.8M | -35.3M | 47.0M | 584K | 81.2M | 175M |
| EBITDA | 56.3M | 57.2M | 69.1M | 60.7M | 28.1M | 3.12M | 25.0M | 107M | 63.1M | 207M | 259M |
| Net Income | 3.93M | -1.08M | 15.5M | 6.09M | -22.5M | -42.6M | -47.9M | 18.8M | -18.5M | 78.3M | 119M |
| EPS | 0.34 | -0.09 | 1.32 | 0.51 | -1.88 | -3.38 | -2.95 | 1.03 | -0.96 | 3.69 | 5.50 |
| Balance Sheet | |||||||||||
| Total Assets | 323M | 412M | 431M | 457M | 461M | 772M | 760M | 904M | 1.28B | 1.44B | 1.57B |
| Total Liabilities | 153M | 237M | 233M | 244M | 265M | 413M | 422M | 447M | 855M | 900M | 931M |
| Shareholders' Equity | 170M | 175M | 197M | 213M | 196M | 359M | 339M | 458M | 429M | 541M | 637M |
| Cash & Short-term Investments | 27.4M | 31.1M | 43.0M | 62.3M | 7.86M | 100M | 48.2M | 221M | 151M | 286M | 436M |
| Total Debt | 121M | 202M | 183M | 186M | 186M | 287M | 287M | 286M | 624M | 325M | 298M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 27.5M | 39.4M | 67.1M | 45.6M | 15.3M | 3.32M | -31.2M | 119M | 64.0M | 185M | 265M |
| Capital Expenditure | 149M | 108M | 10.9M | 27.5M | 68.3M | 23.6M | 16.5M | 18.5M | 17.0M | 34.3M | 37.2M |
| Free Cash Flow | -122M | -68.6M | 56.2M | 18.1M | -53.1M | -20.3M | -47.7M | 100M | 47.1M | 151M | 228M |
| Ratios | |||||||||||
| ROE | 2.3% | -0.6% | 7.9% | 2.9% | -11.5% | -11.9% | -14.1% | 4.1% | -4.3% | 14.5% | 18.7% |
| ROA | 1.2% | -0.3% | 3.6% | 1.3% | -4.9% | -5.5% | -6.3% | 2.1% | -1.4% | 5.4% | 7.6% |
| Net Profit Margin | 3.1% | -0.6% | 7.7% | 3.0% | -10.8% | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% | 11.2% |
| Debt to Equity | 0.71x | 1.15x | 0.93x | 0.87x | 0.95x | 0.80x | 0.85x | 0.62x | 1.46x | 0.60x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ANI Pharmaceuticals Inc dividends
- Dividend yield
- 0.07%
- Forward dividend
- -
- Payout ratio
- 1.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.16M | 0.05 | 1.5% |
| 2024 | USD 1.63M | 0.08 | - |
| 2023 | USD 1.63M | 0.09 | 8.7% |
| 2022 | USD 1.63M | 0.10 | - |
| 2021 | USD 190K | 0.02 | - |
| 2020 | USD 618K | 0.05 | - |
| 2019 | USD 5.74M | 0.48 | 94.2% |
| 2018 | USD 190K | 0.02 | 1.2% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Jul 18, 2013.
Who owns ANI Pharmaceuticals Inc
- Insiders 5.42%
- Institutions 94.58%
- Public & others 0.00%
- Shares outstanding 22.7M
- Free float 19.4M
Top funds holding ANIP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.21M | 5.33% | -0.23% | Oct 2026 |
| Avantis US Small Cap Value ETF | 809K | 3.56% | +0.89% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 656K | 2.89% | +6.80% | Sep 2026 |
| iShares Russell 2000 ETF | 516K | 2.27% | 0.00% | Oct 2026 |
| CC&L Global Alpha - Series A | 279K | 1.23% | +2.45% | Jul 2026 |
| Oberweis Micro-Cap | 256K | 1.13% | +20.61% | Jun 2026 |
| Invesco Pharmaceuticals ETF | 233K | 1.03% | +0.45% | Oct 2026 |
| Fidelity Small Cap Index | 225K | 0.99% | +0.15% | Aug 2026 |
| CREF Total Global Stock Account R3 | 220K | 0.97% | +7.60% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 192K | 0.84% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 183K | 0.81% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 182K | 0.80% | 0.00% | Oct 2026 |
| abrdn US Small Cap Equity Inst Svc | 133K | 0.58% | -0.57% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 131K | 0.58% | +2.88% | Oct 2026 |
| abrdn-Nrth American Sml Comp I Acc USD | 123K | 0.54% | -1.74% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 120K | 0.53% | +36.51% | Aug 2026 |
| Vanguard Russell 2000 ETF | 119K | 0.53% | +1.20% | Sep 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 114K | 0.50% | 0.00% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 114K | 0.50% | 0.00% | Sep 2026 |
| DFA U.S. Targeted Value I | 111K | 0.49% | +41.30% | Sep 2026 |
Top institutions holding ANIP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.96M | 13.02% | +7.69% | Jun 2026 |
| Soleus Capital Management, L.P. | 868K | 3.82% | +5.79% | Jun 2026 |
| Vanguard Capital Management, LLC | 838K | 3.69% | +1.84% | Jun 2026 |
| State Street Corp | 832K | 3.66% | +7.78% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 729K | 3.21% | +16.89% | Sep 2026 |
| TANG CAPITAL MANAGEMENT LLC | 708K | 3.11% | 0.00% | Jun 2026 |
| American Century Companies Inc | 574K | 2.53% | +199.87% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 562K | 2.47% | -0.42% | Jun 2026 |
| Global Alpha Capital Management Ltd. | 558K | 2.45% | +54.47% | Jun 2026 |
| Geode Capital Management, LLC | 536K | 2.36% | +9.65% | Jun 2026 |
| Millennium Management LLC | 507K | 2.23% | -14.33% | Jun 2026 |
| Nuveen, LLC | 415K | 1.83% | +3.15% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 407K | 1.79% | +8.33% | Jun 2026 |
| Ranger Investment Management LP | 343K | 1.51% | -4.70% | Jun 2026 |
| Deutsche Bank AG | 323K | 1.42% | +1.18% | Jun 2026 |
| Amvescap Plc. | 309K | 1.36% | -4.66% | Jun 2026 |
| UBS Group AG | 298K | 1.31% | -40.22% | Jun 2026 |
| Kennedy Capital Management Inc | 296K | 1.30% | +0.66% | Jun 2026 |
| Ameriprise Financial Inc | 287K | 1.26% | +6.33% | Jun 2026 |
| Delaware Management Holdings Inc | 287K | 1.26% | -0.12% | Jun 2026 |
ANI Pharmaceuticals Inc company profile
- Company name
- ANI Pharmaceuticals Inc
- Ticker
- ANIP.US
- Exchange
- USA Stocks
- Listed since
- May 5, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 970
- Fiscal year end
- December
- Address
- 104 Carnegie Center Drive, Princeton, NJ, United States, 08540
- Phone
- 609 759 1810
- Website
- anipharmaceuticals.com
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Princeton, New Jersey.
ANI Pharmaceuticals Inc management
10- Mr. Nikhil LalwaniPresident, CEO & Director · born 1978
- Mr. Stephen P. CareySenior VP of Finance & CFO · born 1971
- Ms. Meredith W. Cook J.D.Senior VP, General Counsel & Corporate Secretary · born 1974
- Mr. Christopher K. MutzSenior VP & Head of Rare Disease · born 1972
- Mr. Ori GutwergSenior Vice President of Generics · born 1975
- Mr. Muthusamy Shanmugam MS R.Ph.Head of R&D and COO of New Jersey Operations · born 1968
- Ms. Irina Rivkind KofflerVice President of Investor Relations
- Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare Disease
- Mr. Chad GassertSenior Vice President of Corporate Development & Strategy · born 1976
- Ms. Krista L. DavisSenior VP & Chief Human Resources Officer · born 1973